| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107074957-B |
| titleOfInvention |
Chimeric antigen receptors (CARs) with mutations in the Fc spacer region and methods of using the same |
| abstract |
Adoptive immunotherapy using T cells genetically redirected via expressing a chimeric antigen receptor (CAR) is a promising approach for cancer treatment. However, this immunotherapy relies in part on the optimal molecular design of CARs that involve extracellular ligand-binding domains linked to intracellular signaling domains via spacers and/or transmembrane sequences. |
| priorityDate |
2014-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |